Alpha-MSH analog peptide (FDA/EMA approved for EPP in specific form)
Afamelanotide
An FDA/EMA-approved melanocortin peptide for erythropoietic protoporphyria phototoxicity; also studied for tanning effects.
- Evidence:
- Strong human evidence
- Status:
- FDA-approved for specific labeled indications
- Reviewed:
- 2026-08-03
Also known as: Afamelanotide, Scenesse
What is Afamelanotide?
An FDA/EMA-approved melanocortin peptide for erythropoietic protoporphyria phototoxicity; also studied for tanning effects.
This profile is educational. It organizes publicly discussed research context for Afamelanotide and related naming aliases — it is not a treatment guide.
Proposed mechanism
MC1R agonism increases eumelanin production in melanocytes, providing photoprotection and skin darkening.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Strong human evidence
Preclinical evidence grade: Strong human evidence
Afamelanotide (Scenesse implant) is approved in the US and EU for EPP to increase pain-free sunlight exposure. Tanning effects occur as a secondary outcome. Distinct from Melanotan II with more selective MC1R profile. Human evidence is strong within EPP indication.
Key uncertainties
- Long-term melanoma surveillance data
- Cosmetic tanning use safety
Research areas being studied
- Photoprotection
- EPP
- Melanogenesis
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Nausea
- Headache
- Facial flushing
- Injection-site reactions
Additional risks & considerations
- Nausea
- Facial flushing
- Darkening of moles/freckles
- Off-label tanning use unapproved
Regulatory status
FDA-approved for specific labeled indications
FDA approved (Scenesse) for erythropoietic protoporphyria.
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is Afamelanotide?
An FDA/EMA-approved melanocortin peptide for erythropoietic protoporphyria phototoxicity; also studied for tanning effects.
How does Afamelanotide work (proposed mechanism)?
MC1R agonism increases eumelanin production in melanocytes, providing photoprotection and skin darkening.
What is Afamelanotide being researched for?
Afamelanotide has been discussed in research contexts including: Photoprotection, EPP, Melanogenesis.
What does current evidence say about Afamelanotide?
Strong human evidence. Afamelanotide (Scenesse implant) is approved in the US and EU for EPP to increase pain-free sunlight exposure. Tanning effects occur as a secondary outcome. Distinct from Melanotan II with more selective MC1R profile. Human evidence is strong within EPP indication.
What safety considerations are noted for Afamelanotide?
Reported or discussed considerations include: Nausea; Headache; Facial flushing; Injection-site reactions; Nausea; Facial flushing; Darkening of moles/freckles; Off-label tanning use unapproved. This is educational information, not medical advice.
Is Afamelanotide FDA approved?
FDA-approved for specific labeled indications. FDA approved (Scenesse) for erythropoietic protoporphyria.
References & sources
- Langendonk JG et al. (2015). Afamelanotide for erythropoietic protoporphyria (CUV039 trial) — NEJM. Evidence type: human.
Prefer interactive tools? Open the PepGuide library entry for Afamelanotide or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.